Peaches Biotech Group

Peaches Biotech is a Spanish regenerative medicine company focused on developing advanced therapies based on the secretome of cells. The company's core technology, PRS (Plasma Rich in Secretomes), utilizes a proprietary process to induce cells to produce specific cytokine cocktails tailored for various therapeutic needs. Their lead candidate, PRS CK Storm, is being evaluated for treating cytokine storms associated with COVID-19 and other inflammatory conditions. Additionally, the company targets musculoskeletal disorders like osteoarthritis and tendonitis, as well as aesthetic applications. Peaches Biotech operates through a network of collaborations with hospitals and research centers to advance its pipeline of biological drugs.